Semaglutide as a MASH Treatment: What You Need to Know
Health ConditionsLiver Disease

MASH: Is Semaglutide Right for You?

MASH: Is Semaglutide Right for You?
Eduardo Monroy Husillos/iStock
By
Updated on December 16, 2025
by

Semaglutide, the popular weight loss and diabetes drug, now has the green light to treat moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). If you have the condition and are considering your treatment options, you may be wondering whether this GLP-1 receptor agonist is the right choice for you.

Available clinical trial data shows that semaglutide can be incredibly helpful for many people with MASH. “It’s not only considered safe for these purposes, but also likely to improve health significantly,” says Jessica Cutler, MD, a weight loss surgeon with the Maryland Bariatric Center at Mercy Medical Center in Baltimore. With that said, it’s not necessarily the best fit for everyone with MASH or related liver conditions.

Semaglutide’s FDA Approval to Treat MASH

In August 2025, semaglutide received an accelerated approval from the U.S. Food and Drug Administration (FDA) as a first-line treatment option for adults with moderate to severe MASH. This decision was based on positive data emerging from an ongoing phase 3 clinical trial, with full approval expected to come once the trial is complete and the FDA reviews the additional data.

The FDA decided that semaglutide should receive accelerated approval for MASH after early results were so positive. After 72 weeks, 63 percent of patients receiving semaglutide resolved their MASH and didn’t experience worse liver scarring or fibrosis, compared with 34 percent of those taking a placebo. Additionally, 37 percent of patients receiving semaglutide improved their liver fibrosis without their MASH worsening, compared with 22 percent of those taking a placebo.

The trial is planned to last a total of 240 weeks, at which point the FDA will look to see whether patients’ improvements in liver inflammation and scarring observed after 72 weeks resulted in fewer deaths, liver transplants, and other liver-related health events.

Semaglutide improves MASH by addressing two of its underlying causes: excess body fat and high blood sugar. Both lead to excess fat accumulation and inflammation in the liver, which can lead to scarring or fibrosis over time.

“By inducing weight loss and improving metabolic health, semaglutide can decrease toxicity from fat accumulation and liver cell damage, allowing the liver to heal and achieve fibrosis regression,” says Naim Alkhouri, MD, hepatologist and chief medical officer at Summit Clinical Research in San Antonio.

People With Diabetes

Semaglutide is sold under two brand names: Wegovy (for weight loss) and Ozempic (for diabetes). Only Wegovy is officially approved for MASH.

The clinical trial exploring the use of semaglutide as a treatment for MASH is testing a weekly 2.4 milligram (mg) dose, the maximum Wegovy dose, which is slightly higher than the maximum weekly 2 mg dose that’s approved for Ozempic to treat diabetes.

 Those who have MASH and diabetes and are already taking semaglutide for the latter may be wondering whether the medication can effectively treat their MASH as well. The answer isn’t yet clear due to the slight difference in these doses.

“Patients already on semaglutide for diabetes who want to treat MASH should talk to their provider to see if dose escalation is right for them,” says A. Sidney Barritt IV, MD, director of hepatology at UNC School of Medicine in Chapel Hill, North Carolina.

People Without Obesity

Not everyone with MASH has obesity. Sometimes people with risk factors like high cholesterol or high blood pressure can develop MASH even though their body mass index (BMI) is considered healthy.

 If you’re in that camp, semaglutide may not be as effective at treating your MASH as those who have obesity, the data suggest.

“[Because] the semaglutide benefit is mostly indirect through control of weight and diabetes, patients without these comorbidities may not receive the same benefits,” says Dr. Barritt.

Instead, it may be worth asking your doctor about other treatment options like resmetirom, which helps improve MASH without weight loss.

Older Adults

Semaglutide is approved to treat adults of all ages with moderate to severe MASH, but if you’re over 60 years old, there are a few concerns of which to be aware.

Rapid weight loss from a GLP-1 puts older adults at higher risk for muscle loss, which may lead to frailty and injuries that make it harder to perform daily activities independently.

 Older age may also make you more prone to experiencing GLP-1-related side effects like nausea, constipation, and dehydration.

 And if you’re taking additional medications, which becomes more common with age, you need to make sure none of those medications interact with semaglutide.

“With careful monitoring, semaglutide can still be considered an effective and safe tool for older adults with MASH,” says Yasika Garcia, MD, an endocrinologist with Medical Offices of Manhattan in New York City. Discuss the benefits and drawbacks with your doctor to determine whether semaglutide is the right treatment option for you.

Children and Teens

MASH may be surprisingly common among children and teens.

 While semaglutide is approved to treat obesity in children over 12 years old, it’s not currently approved to treat MASH in those under 18.
If your child has MASH, talk with their pediatrician about other ways to improve their liver health, such as dietary changes.

Can Semaglutide Treat ‘Fatty Liver’?

Metabolic dysfunction-associated liver disease (MASLD), sometimes referred to as “fatty liver,” is a milder form of MASH. With MASLD, the liver exhibits some excess fat buildup. With MASH, the fat buildup progresses to the point where it causes liver inflammation and scarring.

At this time, semaglutide is only approved to treat MASH, not MASLD.

 However, weight loss is a cornerstone of MASLD treatment.

 So if you have MASLD and you’re overweight or have obesity, your doctor may recommend using semaglutide to reach a healthier weight, which could improve the health of your liver.

Can Semaglutide Treat Severe Liver Disease?

Over time, liver scarring from MASH can lead to severe complications like cirrhosis (advanced liver scarring) or liver failure.

 It can also increase one’s risk for liver cancer. Semaglutide doesn’t appear to be an effective treatment for these advanced complications and isn’t currently recommended as such.

It’s also unclear whether the medication is safe for people with cirrhosis. Though it’s not yet understood why, some research suggests that the rapid weight loss caused by semaglutide could potentially worsen liver scarring.

Warnings and Contraindications

Semaglutide is an effective treatment for MASH, but it’s not appropriate for everyone. You shouldn’t take semaglutide if you have:

  • A personal or family history of medullary thyroid cancer
  • Gastroparesis
  • Multiple endocrine neoplasia type 2
  • Type 1 diabetes
People who are pregnant or breastfeeding should also avoid taking semaglutide.

The Takeaway

  • The FDA has granted accelerated approval for GLP-1 receptor agonist drug semaglutide as a first-line treatment for adults with moderate to severe MASH.
  • Semaglutide works by addressing underlying causes of MASH — namely excess body fat and high blood sugar — leading to weight loss and improved metabolic health that allow the liver to heal.
  • While generally considered safe, semaglutide may be less effective for patients with MASH who don’t also have obesity or diabetes, poses specific risks for older adults (like muscle loss and side effects), and isn’t approved for children or teens or for those navigating severe complications like cirrhosis.
  • Contraindications for taking semaglutide include a personal or family history of medullary thyroid cancer, gastroparesis, type 1 diabetes, and being pregnant or breastfeeding.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’. U.S. Food and Drug Administration. August 15, 2025.
  2. Metabolic Dysfunction-Associated Steatohepatitis (MASH). Cleveland Clinic. May 5, 2025.
  3. Semaglutide (Subcutaneous Route). Mayo Clinic. December 1, 2025.
  4. Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. The New England Journal of Medicine. June 5, 2025.
  5. Suvarna R et al. Efficacy and Safety of Resmetirom, a Selective Thyroid Hormone Receptor-β Agonist, in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis. Scientific Reports. August 26, 2024.
  6. Ren Q et al. Semaglutide Therapy and Accelerated Sarcopenia in Older Adults With Type 2 Diabetes: A 24-Month Retrospective Cohort Study. Drug Design, Development and Therapy. July 3, 2025.
  7. Onoviran OF et al. Effects of Glucagon-Like Peptide 1 Receptor Agonists on Comorbidities in Older Patients With Diabetes Mellitus. Therapeutic Advances in Chronic Disease. July 12, 2019.
  8. Kohli R. Overview of Metabolic Dysfunction-Associated Steatohepatitis in Children. Gastroenterology & Hepatology. April 2025.
  9. Rodriguez N et al. Antiobesity Medications in Adult and Pediatric Obesity and Metabolic Dysfunction–Associated Steatotic Liver Disease. Pharmacological Reviews. July 2025.
  10. AACE Patient Guide to Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction–Associated Steatohepatitis (MASH). American Association of Clinical Endocrinology.
  11. Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice. ClinicalTrials.gov. May 21, 2025.
  12. Suki M et al. Semaglutide in MASLD Patients: Improved Survival and Liver Outcomes. Pharmaceuticals. July 21, 2025.
  13. Loomba R et al. Semaglutide 2·4 mg Once Weekly in Patients With Non-Alcoholic Steatohepatitis-Related Cirrhosis: A Randomised, Placebo-Controlled Phase 2 Trial. The Lancet Gastroenterology & Hepatology. June 2023.
  14. Petta S et al. Focus on Semaglutide 2.4 mg/Week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis. Liver International. November 2025.
  15. Peverelle M et al. Liver Decompensation After Rapid Weight Loss From Semaglutide in a Patient With Non-Alcoholic Steatohepatitis-Associated Cirrhosis. World Journal of Gastroenterology. December 21, 2023.
  16. Semaglutide. MotherToBaby. October 2023.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network
Sean-Hashmi-bio

Sean Hashmi, MD

Medical Reviewer
Castle Connolly Top Doctor, Member of American College of Lifestyle Medicine

Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California. As the regional director for clinical nutrition and weight management at a prominent healthcare organization in Southern California, Dr. Hashmi oversees the development and implementation of cutting-edge nutritional programs and weight management strategies. With his innovative approach and unwavering commitment to providing evidence-based solutions, he is a highly sought-after speaker and a leader in his field.

Hashmi founded the nonprofit organization SelfPrinciple.org to provide accessible and accurate health, nutrition, and wellness information to the public. Through this platform, he shares the latest research findings, empowering individuals to make informed decisions about their well-being. Self Principle also supports children's education by providing scholarships, books, and supplies, so that students have the resources necessary to succeed academically and build a brighter future.

See full bio
Marygrace Taylor

Marygrace Taylor

Author

Marygrace Taylor is an award-winning freelance health and wellness writer with more than 15 years of experience covering topics including women’s health, nutrition, chronic conditions, and preventive medicine. Her work has appeared in top national outlets like Prevention, Parade, Women’s Health, and O, The Oprah Magazine.

She's also the coauthor of three books: Eat Clean, Stay Lean: The Diet, Prevention Mediterranean Table, and Allergy-Friendly Food for Families. She lives in Philadelphia.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network